COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,794 Articles (22,527 medRxiv, 8,267 bioRxiv)

Most recent first Previous |  Page 2639: Articles 26381-26390  | Next

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
Barnes, C. O., West, A. P., Huey-Tubman, K., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., Cetrulo Lorenzi, J. C., Finkin, S., Hagglof, T., Hurley, A., Millard, K. G., Weisblum, Y., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Caskey, M., Robbiani, D., Nussenzweig, M. C., Bjorkman, P. J.
10.1101/2020.05.28.121533 — Posted: 2020-05-29
Regression Analysis of COVID-19 Spread in India and its Different States
Chauhan, P., Kumar, A., Jamdagni, P.
10.1101/2020.05.29.20117069 — Posted: 2020-05-29
Predicting Growth of COVID-19 Confirmed Cases in Each U.S. County with a Population of 50,000 or More
Robertson, L. S.
10.1101/2020.05.29.20117044 — Posted: 2020-05-29
Can medication mitigate the need for a strict lock down?: A mathematical study of control strategies for COVID-19 infection
Ali, M., Imran, M., Khan, A.
10.1101/2020.05.29.20116749 — Posted: 2020-05-29
COVID 19: An SEIR model predicting disease progression and healthcare outcomes for Pakistan
Khan, E. A., Umar, M., Khalid, M.
10.1101/2020.05.29.20116517 — Posted: 2020-05-29
A model for COVID-19 with isolation, quarantine and testing as control measures
Aronna, M. S., Guglielmi, R., Moschen, L. M.
10.1101/2020.05.29.20116897 — Posted: 2020-05-29
Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus
Gao, X., Gong, Y., Zhao, W., He, Z.
10.1101/2020.05.28.120642 — Posted: 2020-05-29 Discussion: Onsite
SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models
Stewart, C. A., Gay, C. M., Ramkumar, K., Cargill, K. R., Cardnell, R. J., Nilsson, M. B., Heeke, S., Park, E. M., Kundu, S. T., Diao, L., Wang, Q., Shen, L., Xi, Y., Della Corte, C. M., Fan, Y., Kundu, K., Pickering, C. R., Johnson, F. M., Zhang, J., Kadara, H., Minna, J. D., Gibbons, D. L., Wang, J., Heymach, J. V., Byers, L. A.
10.1101/2020.05.28.122291 — Posted: 2020-05-29 Discussion: Onsite | Offsite
Evidence of significant natural selection in the evolution of SARS-CoV-2 in bats, not humans
MacLean, O. A., Lytras, S., Singer, J. B., Weaver, S., Kosakovsky Pond, S. L., Robertson, D. L.
10.1101/2020.05.28.122366 — Posted: 2020-05-29
SARS-CoV-2 transmission chains from genetic data: a Danish case study
Bluhm, A., Christandl, M., Gesmundo, F., Ravn Klausen, F., Mancinska, L., Steffan, V., Stilck Franca, D., Werner, A.
10.1101/2020.05.29.123612 — Posted: 2020-05-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).